论文部分内容阅读
目的:探讨黄芪四君子汤联合成分输血对肝癌患者术后免疫功能的影响。方法:将110例接受肝动脉化疗栓塞术(Transcatheter arterial chemoembolization,TACE)治疗的肝癌患者随机分为两组。对照组55例,采用复方甘草酸苷注射液联合成分输血治疗;治疗组55例,采用黄芪四君子汤联合成分输血治疗。比较治疗前后两组外周血T淋巴细胞亚群指标(CD3~+、CD4~+、CD8~+、CD4~+/CD8~+)、自然杀伤细胞(NK)、临床症状的变化情况及不良反应发生情况,并对两组临床疗效进行评价。结果:两组治疗后均CD3~+、CD4~+、NK细胞均上升,中医证候积分均下降,且治疗组上述观察指标均优于对照组,差异均有统计学意义(P<0.05);治疗组总有效率为90.91%(50/55),高于对照组的75.55%(41/55),差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:黄芪四君子汤联合成分输血可有效提高肝癌患者术后免疫功能,缓解临床症状,提高临床疗效。
Objective: To investigate the effect of Huangqi Sijunzi decoction combined with blood transfusion on the immune function of patients with liver cancer. METHODS: One hundred and ten patients with hepatocellular carcinoma treated with transcatheter arterial chemoembolization (TACE) were randomly divided into two groups. In the control group, 55 patients were treated with compound glycyrrhizin injection combined with blood transfusion. In the treatment group, 55 patients were treated with Huangqi Sijunzi decoction combined with blood transfusion. To compare the changes of peripheral blood T lymphocyte subsets (CD3+, CD4+, CD8+, CD4+/CD8+), natural killer (NK), clinical symptoms and adverse reactions before and after treatment Occurrence and evaluation of clinical efficacy in both groups. RESULTS: After treatment, both CD3+, CD4+, and NK cells increased, and the scores of TCM syndromes all decreased. The above observations in the treatment group were all superior to those in the control group, and the differences were statistically significant (P<0.05). The total effective rate in the treatment group was 90.91% (50/55), which was higher than 75.55% (41/55) in the control group. The difference was statistically significant (P<0.05); the incidence of adverse reactions in the two groups was compared, and there was no statistical difference. Significance (P>0.05). Conclusion: The combined blood transfusion of Huangqi Sijunzi decoction can effectively improve the postoperative immune function, relieve the clinical symptoms and improve the clinical efficacy of patients with liver cancer.